77 related articles for article (PubMed ID: 15292283)
1. A randomized trial of remnant ablation--in search of an impossible dream?
Mazzaferri E
J Clin Endocrinol Metab; 2004 Aug; 89(8):3662-4. PubMed ID: 15292283
[No Abstract] [Full Text] [Related]
2. Patients with differentiated thyroid carcinoma benefit from radioiodine remnant ablation.
Haugen BR
J Clin Endocrinol Metab; 2004 Aug; 89(8):3665-7. PubMed ID: 15292284
[No Abstract] [Full Text] [Related]
3. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
4. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer.
Doi SA; Woodhouse NJ
Clin Endocrinol (Oxf); 2000 Jun; 52(6):765-73. PubMed ID: 10848882
[TBL] [Abstract][Full Text] [Related]
5. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal.
Taïeb D; Sebag F; Farman-Ara B; Portal T; Baumstarck-Barrau K; Fortanier C; Bourrelly M; Mancini J; De Micco C; Auquier P; Conte-Devolx B; Henry JF; Mundler O
J Clin Endocrinol Metab; 2010 Jul; 95(7):3283-90. PubMed ID: 20392868
[TBL] [Abstract][Full Text] [Related]
6. Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma.
Taube A; Lundell G
Cancer; 1997 Jan; 79(1):190-1. PubMed ID: 8988747
[No Abstract] [Full Text] [Related]
7. Thyroid stunning after (131)I diagnostic whole-body scanning.
McMenemin RM; Hilditch TE; Dempsey MF; Reed NS
J Nucl Med; 2001 Jun; 42(6):986-7. PubMed ID: 11390566
[No Abstract] [Full Text] [Related]
8. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
9. The HiLo trial: a multicentre randomised trial of high- versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer.
Mallick U; Harmer C; Hackshaw A
Clin Oncol (R Coll Radiol); 2008 Jun; 20(5):325-6. PubMed ID: 18474322
[No Abstract] [Full Text] [Related]
10. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma.
Cherk MH; Kalff V; Yap KS; Bailey M; Topliss D; Kelly MJ
Clin Endocrinol (Oxf); 2008 Dec; 69(6):957-62. PubMed ID: 18419785
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of the effectiveness of radioactive iodine (I-131) treatment of patients with autonomic adenoma of the thyroid].
Sowiński J; Gembicki M
Endokrynol Pol; 1987; 38(4):331-42. PubMed ID: 3454742
[No Abstract] [Full Text] [Related]
12. Randomized trials on radioactive iodine ablation of thyroid remnants for thyroid carcinoma--a critique.
Roos DE; Smith JG
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):493-5. PubMed ID: 10348276
[TBL] [Abstract][Full Text] [Related]
13. Correlation between external exposure and activity in patients undergoing 131I thyroid cancer therapy.
Barquero R; Basurto F; Vega-Carrillo HR; Iñiguez MP; Ferrer N; Esteban R
Health Phys; 2008 Aug; 95(2):227-33. PubMed ID: 18617804
[TBL] [Abstract][Full Text] [Related]
14. [Possible sequelae of the action of radioactive iodine in man].
Il'in LA; Arkhangel'skaia GV
Med Radiol (Mosk); 1973 Aug; 18(8):66-80. PubMed ID: 4801844
[No Abstract] [Full Text] [Related]
15. [Thyroid function following radioiodine resection of autonomous thyroid adenomas].
Heinze HG; Pickardt CR; Swoboda G; Horn K; Erhardt F; Scriba PC
Nuklearmedizin; 1977 Oct; 16(5):224-31. PubMed ID: 593905
[No Abstract] [Full Text] [Related]
16. Thyroid stunning: fact or fiction?
McDougall IR; Iagaru A
Semin Nucl Med; 2011 Mar; 41(2):105-12. PubMed ID: 21272684
[TBL] [Abstract][Full Text] [Related]
17. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients.
Bal CS; Kumar A; Pant GS
J Clin Endocrinol Metab; 2004 Apr; 89(4):1666-73. PubMed ID: 15070929
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human TSH associated with radioiodine does not have further effects on thyroid volume and function after 2 years.
Paz-Filho GJ; Mesa CO; Carvalho GA; Goedert CA; Graf H
Clin Endocrinol (Oxf); 2008 Aug; 69(2):345-6. PubMed ID: 18167135
[No Abstract] [Full Text] [Related]
19. 131I dosimetry and thyroid stunning.
Gerard SK; Park HM
J Nucl Med; 2003 Dec; 44(12):2039-40; author reply 2040. PubMed ID: 14660731
[No Abstract] [Full Text] [Related]
20. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study.
Pacini F; Ladenson PW; Schlumberger M; Driedger A; Luster M; Kloos RT; Sherman S; Haugen B; Corone C; Molinaro E; Elisei R; Ceccarelli C; Pinchera A; Wahl RL; Leboulleux S; Ricard M; Yoo J; Busaidy NL; Delpassand E; Hanscheid H; Felbinger R; Lassmann M; Reiners C
J Clin Endocrinol Metab; 2006 Mar; 91(3):926-32. PubMed ID: 16384850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
